NM_001001344.3:c.3320G>A
Variant summary
Our verdict is Pathogenic. Variant got 11 ACMG points: 11P and 0B. PM2PP3PP5_Very_Strong
The NM_001001344.3(ATP2B3):c.3320G>A(p.Gly1107Asp) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00000186 in 1,076,121 control chromosomes in the GnomAD database, with no homozygous occurrence. There are no hemizygote samples in GnomAD. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_001001344.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 11 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 27
GnomAD4 exome AF: 0.00000186 AC: 2AN: 1076121Hom.: 0 Cov.: 32 AF XY: 0.00 AC XY: 0AN XY: 348883
GnomAD4 genome Cov.: 27
ClinVar
Submissions by phenotype
Inborn genetic diseases Pathogenic:1
The c.3320G>A (p.G1107D) alteration is located in coding exon 19 of the ATP2B3 gene. This alteration results from a G to A substitution at nucleotide position 3320, causing the glycine (G) at amino acid position 1107 to be replaced by an aspartic acid (D). Based on data from the Genome Aggregation Database (gnomAD), the ATP2B3 c.3320G>A alteration was observed in 0.0014% (2/139053) of total alleles studied, with a frequency of 0.0087% (2/23071) in the Latino/Admixed American subpopulation; however this variant was flagged as a low confidence call. No hemizygotes were observed. This alteration has been observed to co-segregate with disease in an X-linked recessive fashion in 2 unrelated families in which affected males presented with childhood ataxia and various other movement abnormalities (Bertini, 2000; Feyma, 2016; Zanni, 2012) The p.G1107 amino acid is conserved in most available vertebrate species. Functional analysis demonstrated that the p.G1107D alteration interferes with the calmodulin-binding domain (CaM-BD) and it's ability to bind to calmodulin in order to activate the enzyme. In addition, protein with the p.G1107D alteration also has a dysfunctional autoinhibitory mechanism (Calì, 2017). Further in vitro studies observed that overexpressed enzyme with this alteration retains Ca2+ in the cells longer than wildtype suggesting impaired transporting activity (Zanni, 2012). The p.G1107D alteration is predicted to be deleterious by in silico analysis. Based on the available evidence, this alteration is classified as likely pathogenic. -
X-linked progressive cerebellar ataxia Pathogenic:1
- -
not provided Pathogenic:1
The G1107D variant in the ATP2B3 gene has been reported previously as a hemizygous in an uncle and his nephew with spinocerebellar ataxia-1 (Zanni et al., 2012). Functional studies expressing the mutated protein in Hela cells showed impaired extrusion of intracellular calcium with prolonged retention of cytoplasmic calcium (Zanni et al., 2012). The G1107D variant is not observed at a significant frequency in large population cohorts (Lek et al., 2016; 1000 Genomes Consortium et al., 2015; Exome Variant Server). The G1107D variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position that is conserved across species. In silico analysis predicts this variant is probably damaging to the protein structure/function. The G1107D variant is a strong candidate for a pathogenic variant, however the possibility it may be a rare benign variant cannot be excluded. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at